A phase 3, randomized trial of magrolimab in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia ineligible for intensive chemotherapy (ENHANCE-3)
| Main Authors: | , , , , , |
|---|---|
| Format: | Conference item |
| Language: | English |
| Published: |
Wiley
2022
|